## **Supporting Information**

## Teijaro et al. 10.1073/pnas.1400593111




Fig. S1. Sphingosine-1-phosphate-1 receptor (S1P<sub>1</sub>R) agonist therapy suppresses innate immune cell recruitment and activation independent of Toll-like receptor (TLR)3 or TLR7 signaling. TLR3 $^{-/-}$  (A) or TLR7 $^{-/-}$  (B) mice were infected with 1 × 10 $^4$  PFU WSN influenza virus and either vehicle (water) or CYM5442 (2 mg/kg) were administered intratracheally to mice. (A and B) Level of expression of the early activation marker CD69 on macrophages and NK cells from collagenase-digested lungs at 48 h postinfection. \*P < 0.05, \*P < 0.01, \*P < 0.05. Results are representative of two independent experiments and five mice per group.




Fig. S2. S1P<sub>1</sub>R agonist therapy suppresses innate immune cell activation independent of endosomal TLR signaling. Expression levels of the early activation marker CD69 on macrophages and NK cells from collagenase-digested lungs at 48 h postinfection in 3d mice. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.005. Results are representative of two independent experiments and five mice per group.




Fig. S3. IL-1R signaling is required for innate cellular activation and recruitment following influenza virus infection. (A-C) IL-1 $R^{-/-}$  or IL-1 $R^{+/+}$  control mice were infected with 1 × 10<sup>4</sup> PFU WSN influenza virus and recruitment of activated macrophages/monocytes and NK cells (A), expression levels of the early activation marker CD69 (B), and total numbers of neutrophils (C) were quantified 48 h postinfection in collagenase digested lungs. (D and E) Bone marrow chimeras between IL-1 $R^{+/+}$  and IL-1 $R^{-/-}$  mice by injection of either IL-1 $R^{+/-}$  bone marrow cells into lethally irradiated IL-1 $R^{-/-}$  mice or vice versa. IL-1 $R^{+/+}$  bone marrow cells injected into irradiated IL-1 $R^{-/-}$  mice as controls. Chimeric mice were infected with 1 × 10<sup>4</sup> PFU WSN influenza virus percentages (D) and expression levels (E) of CD69<sup>+</sup> on macrophages and NK cells from collagenase-digested lungs at 48 h postinfection in 3d mice. (F-H) IL-1 $R^{-/-}$  or IL-1 $R^{+/+}$  control mice were infected with 1 × 10<sup>4</sup> PFU WSN influenza virus and either vehicle (water) or CYM5442 (2 mg/kg) were administered intratracheally to mice. Percentage (F) and total numbers (F) of macrophages/monocytes were quantified 48 h postinfection in collagenase-digested lungs. (F) Total numbers of neutrophils in the lungs of IL-1F1-1/- mice 48 h postinfluenza virus infection.\*F1 Co.05, \*F2 Co.01, \*\*\*F3 Co.05. Results are representative of two to three independent experiments and five mice per group.




Fig. S4. S1P<sub>1</sub>R agonist treatment globally blunts innate immune signaling converging downstream of multiple innate sensing pathways. The figure depicts (A) redundant innate signaling pathways triggered by influenza virus infection that induce the expression of inflammatory genes. (B) S1P<sub>1</sub>R agonist signaling through an unidentified mechanism results in the suppression of inflammatory gene expression at a point common to multiple signaling pathways. Based on our data presented in this study, we postulate that S1P<sub>1</sub>R agonist inhibition occurs at one or more of the indicated points depicted in the figure. IPS-1, IFN-β promoter stimulator-1; MDA-5, melanoma differentiation-associated-5; MyD88, myeloid differentiation primary response gene 88; RIG-I, retinoic acid-inducible gene.